


CLAIM AMENDMENT

1. (Currently amended): A method for inhibiting the growth of tumor cells in an individual comprising administering to the individual a pharmacologically effective dose of a compound having a structural formula



Wherein X is oxygen or nitrogen;

Y is oxygen or NR⁶

R¹ is -C₁₋₁₀alkylene-COOH, -C₁₋₄alkylene-CONH₂, -C₁₋₄alkylene-COO-C₁₋₄alkyl, -C₁₋₄alkylene-CON(C₁₋₄alkylene-COOH)₂, -C₁₋₄alkylene-OH, -C₁₋₄alkylene-NH₃-halo or -C₁₋₄alkylene-OSO₂NH(C₁₋₄alkyl), -C₁₋₄alkylene-COO-C₁₋₄alkyl, -C₁₋₁₀alkylene-CO-SH, -C₁₋₄alkylene-CO-S(C₁₋₄alkyl), -C₁₋₄alkylene-CS-NH₂, -C₁₋₄alkylene-CO-NH_(2-n)(C₁₋₄alkyl)_n wherein n is 2 or 1, -C₁₋₄alkylene-SO₂-O(C₁₋₄alkyl), -C₁₋₄alkylene-OSO₂-O(C₁₋₄alkyl), -C₁₋₄alkylene-OP(O-C₁₋₄alkyl)₃, or -C₁₋₁₀alkylene-CN;

R² and R³ are independently hydrogen or R⁴;

R⁴ is methyl;

R⁵ is a C₇₋₁₆ olefinic group containing 3 to 5 ethylenic bonds;

R⁶ is hydrogen or methyl.

2. (Currently amended): The method of claim 1, wherein said compound is an α -tocotrienol, a γ -tocotrienol or a δ -tocotrienol.

3. (Original): The method of claim 1, wherein said compound is 2,5,7,8-tetramethyl-2R-(4,8,12-trimethyl-3,7,11 E:Z tridecatrien) chroman-6-yloxy) acetic acid.

4. (Previously presented): The method of claim 1, wherein said compound induces apoptosis, DNA synthesis arrest, cell cycle arrest, or cellular differentiation in cells comprising said tumor.

5. (Previously presented): The method of claim 1, wherein said compound is administered in a dose of about 1 mg/kg to about 60 mg/kg.


6. (Previously presented): The method of claim 5, wherein administration of said composition is oral, topical, liposomal/aerosol, intraocular, intranasal, parenteral, intravenous, intramuscular, or subcutaneous.

7. (Canceled)

8. (Currently amended): The method of claim 1, wherein said tumor cells comprise an ovarian cancer, a cervical cancer, an endometrial cancer, a bladder cancer, a lung cancer, a breast cancer, a testicular cancer, a prostate cancer, a glioma, a fibrosarcoma, a retinoblastoma, a melanoma, a soft tissue sarcoma, an osteosarcoma, a leukemia, a colon cancer, a carcinoma of the kidney, a pancreatic cancer, a basal cell carcinoma, or a squamous cell carcinoma.

9-13. (Canceled)

14. (Currently amended): A method of inducing apoptosis of a cell, comprising the step of contacting said cell with a pharmacologically effective dose of a compound having a structural formula



Wherein X is oxygen or nitrogen;

Y is oxygen or NR⁶

R¹ is -C₁₋₁₀alkylene-COOH, -C₁₋₄alkylene-CONH₂, -C₁₋₄alkylene-COO-C₁₋₄alkyl, -C₁₋

$\text{C}_{1-4}\text{alkylene-CON}(\text{C}_{1-4}\text{alkylene-COOH})_2$, $-\text{C}_{1-4}\text{alkylene-OH}$, $-\text{C}_{1-4}\text{alkylene-NH}_3\text{-halo}$ or $-\text{C}_{1-4}\text{alkylene-OSO}_2\text{NH}(\text{C}_{1-4}\text{alkyl})$, $-\text{C}_{1-4}\text{alkylene-COO-C}_{1-4}\text{alkyl}$, $-\text{C}_{1-10}\text{alkylene-CO-SH}$, $-\text{C}_{1-4}\text{alkylene-CO-S}(\text{C}_{1-4}\text{alkyl})$, $-\text{C}_{1-4}\text{alkylene-CS-NH}_2$, $-\text{C}_{1-4}\text{alkylene-CO-NH}_{(2-n)}(\text{C}_{1-4}\text{alkyl})_n$ wherein n is 2 or 1, $-\text{C}_{1-4}\text{alkylene-SO}_2\text{-O}(\text{C}_{1-4}\text{alkyl})$, $-\text{C}_{1-4}\text{alkylene-OSO}_2\text{-O}(\text{C}_{1-4}\text{alkyl})$, $-\text{C}_{1-4}\text{alkylene-OP(O-C}_{1-4}\text{alkyl})_3$, or $-\text{C}_{1-10}\text{alkylene-CN}$;

R^2 and R^3 are independently hydrogen or R^4 ;

R^4 is methyl;

R^5 is a C_{7-16} olefinic group containing 3 to 5 ethylenic bonds;

R^6 is hydrogen or methyl.

15. (Currently amended): The method of claim 14, wherein said compound is an α -tocotrienol, a γ -tocotrienol or a δ -tocotrienol.

16. (Original): The method of claim 14, wherein said compound is 2,5,7,8-tetramethyl-2R-(4,8,12-trimethyl-3,7,11 E:Z tridecatrien) chroman-6-yloxy) acetic acid.

17. (Canceled)

18. (Previously presented): The method of claim 1, wherein R^1 is $-\text{C}_{1-10}\text{alkylene-COOH}$.

19. (Previously presented): The method of claim 1, wherein R^1 is $-\text{C}_{1-4}\text{alkylene-CONH}_2$.

20. (Previously presented): The method of claim 1, wherein R^1 is $-\text{C}_{1-4}\text{alkylene-COO-C}_{1-4}\text{alkyl}$.

21. (Previously presented): The method of claim 1, wherein R^1 is $-\text{C}_{1-4}\text{alkylene-CON}(\text{C}_{1-4}\text{alkylene-COOH})_2$.

22. (Previously presented): The method of claim 1, wherein R^1 is $-\text{C}_{1-4}\text{alkylene-OH}$.

23. (Previously presented): The method of claim 1, wherein R^1 is $-\text{C}_{1-4}\text{alkylene-NH}_3\text{-halo}$.

24. (Previously presented): The method of claim 1, wherein R^1 is $-\text{C}_{1-4}\text{alkylene-OSO}_2\text{NH}(\text{C}_{1-4}\text{alkyl})$.

₄alkyl).

25. (Previously presented): The method of claim 1, wherein R¹ is -C₁₋₄alkylene-COO-C₁₋₄alkyl.

26. (Previously presented): The method of claim 1, wherein R¹ is -C₁₋₁₀alkylene-CO-SH.

27. (Previously presented): The method of claim 1, wherein R¹ is -C₁₋₄alkylene-CO-S(C₁₋₄alkyl).

28. (Previously presented): The method of claim 1, wherein R¹ is -C₁₋₄alkylene-CS-NH₂.

29. (Previously presented): The method of claim 1, wherein R¹ is -C₁₋₄alkylene-CO-NH_(2-n)(C₁₋₄alkyl)_n wherein n is 2 or 1.

30. (Previously presented): The method of claim 1, wherein R¹ is -C₁₋₄alkylene-SO₂-O(C₁₋₄alkyl).

31. (Previously presented): The method of claim 1, wherein R¹ is -C₁₋₄alkylene-OSO₂-O(C₁₋₄alkyl).

32. (Previously presented): The method of claim 1, wherein R¹ is -C₁₋₄alkylene-OP(O-C₁₋₄alkyl)₃.

33. (Previously presented): The method of claim 1, wherein R¹ is -C₁₋₁₀alkylene-CN.

34. (Previously presented): The method of claim 1, wherein R² is hydrogen.

35. (Previously presented): The method of claim 1, wherein R² is methyl.

36. (Previously presented): The method of claim 1, wherein R³ is hydrogen.

37. (Previously presented): The method of claim 1, wherein R³ is methyl.

38. (Previously presented): The method of claim 1, wherein R⁴ is methyl.

39. (Previously presented): The method of claim 1, wherein R⁵ is a C₇₋₁₆ olefinic group containing 3 to 5 ethylenic bonds.

40. (Previously presented): The method of claim 1, wherein R⁶ is methyl.

41. (Previously presented): The method of claim 1, wherein R⁶ is hydrogen.

42. (Previously presented): The method of claim 14, wherein R¹ is -C₁₋₁₀alkylene-COOH.

43. (Previously presented): The method of claim 14, wherein R¹ is -C₁₋₄alkylene-CONH₂.

44. (Previously presented): The method of claim 14, wherein R¹ is -C₁₋₄alkylene-COO-C₁₋₄alkyl.

45. (Previously presented): The method of claim 14, wherein R¹ is -C₁₋₄alkylene-CON(C₁₋₄alkylene-COOH)₂.

46. (Previously presented): The method of claim 14, wherein R¹ is -C₁₋₄alkylene-OH.

47. (Previously presented): The method of claim 14, wherein R¹ is -C₁₋₄alkylene-NH₃-halo.

48. (Previously presented): The method of claim 14, wherein R¹ is -C₁₋₄alkylene-OSO₂NH(C₁₋₄alkyl).

49. (Previously presented): The method of claim 14, wherein R¹ is -C₁₋₄alkylene-COO-C₁₋₄alkyl.

50. (Previously presented): The method of claim 14, wherein R¹ is -C₁₋₁₀alkylene-CO-SH.

51. (Previously presented): The method of claim 14, wherein R¹ is -C₁₋₄alkylene-CO-S(C₁₋₄alkyl).

52. (Previously presented): The method of claim 14, wherein R¹ is -C₁₋₄alkylene-CS-NH₂.

53. (Previously presented): The method of claim 14, wherein R¹ is -C₁₋₄alkylene-CO-NH_(2-n)(C₁₋₄alkyl)_n wherein n is 2 or 1.

54. (Previously presented): The method of claim 14, wherein R¹ is -C₁₋₄alkylene-SO₂-O(C₁₋₄alkyl).

55. (Previously presented): The method of claim 14, wherein R¹ is -C₁₋₄alkylene-OSO₂-O(C₁₋₄alkyl).

56. (Previously presented): The method of claim 14, wherein R¹ is -C₁₋₄alkylene-OP(O-C₁₋₄alkyl)₃.

57. (Previously presented): The method of claim 14, wherein R¹ is -C₁₋₁₀alkylene-CN.

58. (Previously presented): The method of claim 14, wherein R² is hydrogen.

59. (Previously presented): The method of claim 14, wherein R² is methyl.

60. (Previously presented): The method of claim 14, wherein R³ is hydrogen.

61. (Previously presented): The method of claim 14, wherein R³ is methyl.

62. (Previously presented): The method of claim 14, wherein R⁴ is methyl.

63. (Previously presented): The method of claim 14, wherein R⁵ is a C₇₋₁₆ olefinic group containing 3 to 5 ethylenic bonds.

64. (Previously presented): The method of claim 14, wherein R⁶ is methyl.

65. (Previously presented): The method of claim 14, wherein R⁶ is hydrogen.